Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Past Issues
    • Accepted Articles
    • Email Alerts
    • RSS
    • Terms of Use
  • About PDA JPST
    • JPST Editors and Editorial Board
    • About/Vision/Mission
    • Paper of the Year
  • Author & Reviewer Resources
    • Author Resources / Submit
    • Reviewer Resources
  • JPST Access and Subscriptions
    • PDA Members
    • Institutional Subscriptions
    • Nonmember Access
  • Support
    • Join PDA
    • Contact
    • Feedback
    • Advertising
    • CiteTrack
  • .
    • Visit PDA
    • PDA Letter
    • Technical Reports
    • news uPDATe
    • Bookstore

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
PDA Journal of Pharmaceutical Science and Technology
  • .
    • Visit PDA
    • PDA Letter
    • Technical Reports
    • news uPDATe
    • Bookstore
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
PDA Journal of Pharmaceutical Science and Technology

Advanced Search

  • Home
  • Content
    • Current Issue
    • Past Issues
    • Accepted Articles
    • Email Alerts
    • RSS
    • Terms of Use
  • About PDA JPST
    • JPST Editors and Editorial Board
    • About/Vision/Mission
    • Paper of the Year
  • Author & Reviewer Resources
    • Author Resources / Submit
    • Reviewer Resources
  • JPST Access and Subscriptions
    • PDA Members
    • Institutional Subscriptions
    • Nonmember Access
  • Support
    • Join PDA
    • Contact
    • Feedback
    • Advertising
    • CiteTrack
  • Follow pda on Twitter
  • Visit PDA on LinkedIn
  • Visit pda on Facebook
Article CommentaryCommentary

Risk-based Strategy to Determine Testing Requirement for the Removal of Residual Process Reagents as Process-related Impurities in Bioprocesses

Jinshu Qiu, Kim Li, Karen Miller and Anil Raghani
PDA Journal of Pharmaceutical Science and Technology May 2015, 69 (3) 334-345; DOI: https://doi.org/10.5731/pdajpst.2015.01056
Jinshu Qiu
1Product Development, Amgen Inc., Thousand Oaks, CA USA; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jqiu@amgen.com araghani@amgen.com
Kim Li
2Environment, Health, Safety and Sustainability, Amgen Inc., Thousand Oaks, CA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen Miller
1Product Development, Amgen Inc., Thousand Oaks, CA USA; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anil Raghani
1Product Development, Amgen Inc., Thousand Oaks, CA USA; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jqiu@amgen.com araghani@amgen.com
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 69 no. 3 334-345
DOI 
https://doi.org/10.5731/pdajpst.2015.01056
PubMed 
26048741

Published By 
Parenteral Drug Association (PDA)
Print ISSN 
1079-7440
Online ISSN 
1948-2124
History 
  • Published online June 4, 2015.

Copyright & Usage 
© PDA, Inc. 2015

Author Information

  1. Jinshu Qiu1,*,
  2. Kim Li2,
  3. Karen Miller1 and
  4. Anil Raghani1,*
  1. 1Product Development, Amgen Inc., Thousand Oaks, CA USA; and
  2. 2Environment, Health, Safety and Sustainability, Amgen Inc., Thousand Oaks, CA USA
  1. ↵*Corresponding Authors: jqiu{at}amgen.com, 805-447-3183; araghani{at}amgen.com, 805-447-0668.
View Full Text

Cited By...

  • 8 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Recent developments and challenges of biocatalytic processes in the pharmaceutical industry
    Katrin Rosenthal, Stephan Lütz
    Current Opinion in Green and Sustainable Chemistry 2018 11
  • Safety risk management for low molecular weight process‐related impurities in monoclonal antibody therapeutics: Categorization, risk assessment, testing strategy, and process development with leveraging clearance potential
    Haibin Luo, Yuling Li, David Robbins, Sheau‐Chiann Wang, Guoling Xi, Matthew Cox, Simone M. Nicholson, Chenghong Wei, Timothy M. Pabst, William K. Wang
    Biotechnology Progress 2021 37 3
  • Product safety aspects of plant molecular farming
    J. F. Buyel
    Frontiers in Bioengineering and Biotechnology 2023 11
  • Development of novel gradient RP-HPLC method for separation of dapagliflozin and its process-related impurities: insight into stability profile and degradation pathway, identification of degradants using LCMS
    Bhawani Sunkara, Ganesh Kumar Tummalapalli Naga Venkata
    Future Journal of Pharmaceutical Sciences 2023 9 1
  • Analytical control strategy for biologics. Part I: Foundations
    Brent S. Kendrick, Krishnan Sampathkumar, John P. Gabrielson, Da Ren
    Journal of Pharmaceutical Sciences 2025 114 7
  • Development and validation of LC–MS/MS method for quantification of protease inhibitor Pepstatin A to monitor its robust clearance in vaccine downstream process.
    Tingting Jiang, Nathan Edwards, Neelima Sukumar, Michael Mayers, John Higgins, Hari Kosanam
    Journal of Chromatography B 2023 1215
  • ICH Quality Guidelines
    Anil Raghani, Kim Li, Jeanine L. Bussiere, Joel P. Bercu, Jinshu Qiu
    2017
  • The Challenge of CMC Regulatory Compliance for Biopharmaceuticals
    John Geigert
    2019
PreviousNext
Back to top

In This Issue

PDA Journal of Pharmaceutical Science and Technology: 69 (3)
PDA Journal of Pharmaceutical Science and Technology
Vol. 69, Issue 3
May/June 2015
  • Table of Contents
  • Index by Author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on PDA Journal of Pharmaceutical Science and Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Risk-based Strategy to Determine Testing Requirement for the Removal of Residual Process Reagents as Process-related Impurities in Bioprocesses
(Your Name) has sent you a message from PDA Journal of Pharmaceutical Science and Technology
(Your Name) thought you would like to see the PDA Journal of Pharmaceutical Science and Technology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
5 + 15 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Risk-based Strategy to Determine Testing Requirement for the Removal of Residual Process Reagents as Process-related Impurities in Bioprocesses
Jinshu Qiu, Kim Li, Karen Miller, Anil Raghani
PDA Journal of Pharmaceutical Science and Technology May 2015, 69 (3) 334-345; DOI: 10.5731/pdajpst.2015.01056

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Risk-based Strategy to Determine Testing Requirement for the Removal of Residual Process Reagents as Process-related Impurities in Bioprocesses
Jinshu Qiu, Kim Li, Karen Miller, Anil Raghani
PDA Journal of Pharmaceutical Science and Technology May 2015, 69 (3) 334-345; DOI: 10.5731/pdajpst.2015.01056
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Measured Safety Margin and Specification
    • Conclusion
    • References:
  • Figures & Data
  • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Retrospective Evaluation of Cycled Resin in Viral Clearance Studies—A Multiple Company Collaboration—Post ICH Q5A(R2) Review
  • A Risk Based Approach for Pre-Use/Post-Sterilization Integrity Test Simulation During Bacterial Retention Testing as Part of the Process Specific Filter Validation of Sterilizing Grade Filters
  • Challenges and Solutions to Manufacturing of Low-Viscosity, Ultra-High Concentration IgG1 Drug Products: From Late Downstream Process to Final Fill Finish Processing
Show more Commentary

Similar Articles

Keywords

  • Clearance testing strategy
  • Process reagents
  • Process-related impurity
  • Safety margin
  • GRAS reagents
  • PSC reagents

Readers

  • About
  • Table of Content Alerts/Other Alerts
  • Subscriptions
  • Terms of Use
  • Contact Editors

Author/Reviewer Information

  • Author Resources
  • Submit Manuscript
  • Reviewers
  • Contact Editors

Parenteral Drug Association, Inc.

  • About
  • Advertising/Sponsorships
  • Events
  • PDA Bookstore
  • Press Releases

© 2025 PDA Journal of Pharmaceutical Science and Technology Print ISSN: 1079-7440  Digital ISSN: 1948-2124

Powered by HighWire